In this expert presentation, Dr Wallace Brownlee, discusses aspects of the diagnosis of multiple sclerosis. In details, he reviews background and epidemiology as well as phenotypes and presentations of MS. Using patient cases as examples, he also explains which investigations should be performed to make a diagnosis. Because MS is often misdiagnoses, Dr Brownlee ends by presenting common reasons for misdiagnosis.
Diagnosis of multiple sclerosis
Consultant Neurologist, National Hospital for Neurology and Neurosurgery, Queen Square
© 2017 Aptus Health International, Inc. All rights reserved.
9mins - Expert presentations By Vicky Tittle
Dr Vicky Tittle, from 56 Dean Street in London, UK, reviews the reasons to test for HIV, when and how to test and which key populations should receive testing. Specific focus is placed on British guidelines for HIV testing and importance to conduct key initial investigations.
13mins - Expert presentations By Professor David Livermore
Future developments in antimicrobial agents
Professor David Livermore highlights increasing resistance and the major bacterial challenges we face. Beta-lactams, the most widely used antibiotic are losing their efficacy. However, there is hope for antimicorbial agents. Cefiderocol, murepavadin and gepotidacin/zoliflodacin all show promise in replacing spent antibiotics. Further, non-antibiotic approaches and improved molecular diagnostics, while not currently comprehensive, could revolutionise the field.
12mins - Expert presentations By Lars Bastholt
Treatment of Metastatic Melanoma in 2019
As a leading expert in the field of metastatic melanoma, Lars Bastholt runs through the recent developments that have transformed treatment of this disease and vastly improved average prognosis. He covers the major trials of drugs targeting the activated MAPK pathway and those blocking CTLA4 and PD1. There is information on which toxicities to look out for with particular regimens, as well as useful guidance on selecting the most appropriate treatment according to patient factors such as disease aggressiveness and molecular biomarkers. Finally, Professor Bastholt looks to trials in progress and how treatment may change in the near future.